Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | PHASE2 | COMPLETED | 190 | — | — | May 10, 2017 | Oct 2, 2019 | Feb 3, 2021 | 1 | China |
OS was defined as the time from randomization to death due to any cause. Median OS in all participants is presented.
| Arm | Type | Description |
|---|---|---|
| IBI308 | EXPERIMENTAL | IBI308 200mg Intravenous drip every three weeks |
| paclitaxel/irinotecan | ACTIVE_COMPARATOR | paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks |
| Name | Type | Description |
|---|---|---|
| IBI308 | BIOLOGICAL | IBI308 200mg Intravenous drip every three weeks； |
| paclitaxel/ irinotecan | DRUG | paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks |
Inclusion Criteria: 1. Histologically or cytologically confirmed locally advanced unresectable or metastatic esophageal squamous cell carcinoma (excluding mixed adenosquamous carcinoma and other pathological types). 2. Imaging evidence (e.g. CT scan) or clinical evidence (e.g. cytological report of...